Previous studies have demonstrated that a substantial number of patients with communityacquired pneumonia (CAP) experienced CAP-related symptoms up to 3 months after the completion of antibiotic treatment. We evaluated the frequency of symptoms in a cohort of 535 patients with CAP who presented to a hospital emergency department and completed symptom questionnaires 2 and 6 weeks after the completion of a course of antibiotic therapy. Six weeks after cessation of antibiotic therapy, 64% of patients still reported у1 CAP-related symptoms. Exploratory analyses were performed to identify potential predictors of complete symptom resolution. Logistic regression analysis identified younger age, absence of asthma or chronic obstructive pulmonary disease, and levofloxacin treatment as predictors of complete symptom resolution (all ). Randomized controlled trials should be performed to eval-P ! .05 uate the relative efficacy of different antibiotic therapies on the rate of resolution of symptoms.
naires that asked about the presence of symptoms 0, 7, 30, and 90 days after the initial diagnosis of CAP. The majority of patients continued to experience symptoms of CAP 30 days after the initiation of treatment. Moreover, even after 90 days had elapsed, the prevalence of each symptom was still nearly twice what it was before the pneumonia diagnosis.
In a second study, the same group of investigators evaluated 134 low-risk patients with CAP who were part of a prospective study of a new emergency department protocol [7] . The analysis was restricted to patients who had returned a self-administered symptom questionnaire at the baseline visit and 7, 14, 21, and 28 days thereafter. Although this study included patients who were less ill, 35% of the patients reported у1 disease-related symptoms at the final visit. Thus it appears that the resolution of symptoms is delayed in many patients.
No previous studies have assessed the factors that determine persistence of symptoms in this population of patients. In the current study, we assessed a cohort of patients presenting to a hospital emergency department who participated in a randomized trial that evaluated levofloxacin therapy for CAP [8] . Our objectives were to determine the proportion of patients with complete resolution of symptoms 6 weeks after the completion of antibiotic therapy and to identify predictors of a complete resolution of symptoms. We also assessed the prevalence and predictors of gastrointestinal complaints because a previous clinical trial, conducted in patients with sinusitis, had suggested that levofloxacin might have better gastrointestinal tolerability than other antibiotics that are used to treat respiratory tract infections [9] .
Patients and Methods
Study sites. Nineteen Canadian teaching and community hospitals participated in this study.
Study population. The patients described in the current study consisted of a cohort of 535 participants in the CommunityAcquired Pneumonia Intervention Trial Assessing Levofloxacin (CAPITAL) Study, a randomized controlled trial that evaluated a critical pathway for the management of CAP [8] . All adult patients who presented to the emergency department with CAP from 1 January through 31 July 1998 were considered for enrollment. Patients were eligible if they presented with у2 signs or symptoms of CAP and had chest radiograph that indicated an opacity compatible with the presence of acute pneumonia. Signs or symptoms of CAP were a temperature 138ЊC, complaints of a productive cough, chest pain, shortness of breath, or the presence of crackles on auscultation. We excluded patients who had evidence of immune deficiency or chronic liver failure, who required direct admission to the intensive care unit, who were pregnant or nursing, or who had alcoholism. Patients who were admitted to the hospital and those who were discharged from the emergency department completed follow-up symptom questionnaires 2 and 6 weeks after therapy. Only patients who provided complete symptom data for both the 2-and 6-week questionnaires were included in the study. Baseline characteristics. Demographic data were collected at the time of enrollment by means of patient interviews and standardized diagnostic assessments. The components required for the calculation of the Pneumonia Severity Index (PSI) [10] were obtained at the baseline visit. The PSI is a validated measure of disease severity. Scores range from ∼10 to 250 points; higher scores indicate more severe disease.
Outcome assessments. This study used data from the 2-and 6-week posttherapy follow-up questionnaires, most of which were administered by a research nurse by telephone interview; a few were completed by the patient and returned by mail. The research nurse asked the question, "During the past week, have you had any of the following symptoms?" and recorded the presence or absence of each of the following 10 symptoms. CAP-related symptoms were the occurrence of fever, cough, shortness of breath, chest pain, sputum production, and fatigue. Gastrointestinal symptoms were vomiting, nausea, diarrhea, and abdominal pain.
The following factors were evaluated as potential predictors of symptoms of CAP: age, weight, sex, pulse rate, systolic and diastolic blood pressure, respiratory rate, temperature, hemoglobin, WBC count, serum urea, O 2 saturation, PSI score, nursing home residence, pleural effusion, asthma, chronic obstructive pulmonary disease (COPD), neoplastic disease, liver disease, renal disease, cerebrovascular disease, presence of congestive heart failure, treatment in the critical pathway, and levofloxacin, b-lactam, or macrolide therapy.
For the evaluation of potential predictors of gastrointestinal symptoms, only the following clinically plausible factors were examined: age, sex, PSI score, asthma, COPD, neoplastic disease, liver disease, renal disease, cerebrovascular disease, presence of congestive heart failure, treatment in the critical pathway, and levofloxacin, b-lactam, or macrolide therapy.
Statistical methods. Demographic characteristics were evaluated with descriptive statistics and 95% CIs. Exploratory analyses by logistic regression were performed that examined the relationship between the potential predictors and symptom resolution (both CAP-related and gastrointestinal) 6 weeks after therapy. Data from the week 2 questionnaire were not used because we expected that the majority of the patients would continue experiencing symptoms at that time. Predictors that were significantly associated with these outcomes by univariate analyses at the .05 level were further examined in a multivariate model in a stepwise manner.
Results
Baseline characteristics. A total of 1743 patients were enrolled in the CAPITAL Study. Data from 535 of these patients were included in the current study. The demographic characteristics of the patients are shown in Resolution of CAP-related symptoms. The proportion of patients with symptoms of CAP decreased over time ( figure 1) . Fatigue was the most common complaint; 66.7% and 45.0% of patients at 2 and 6 weeks, respectively, had this symptom. Two weeks after the completion of therapy, 55.5% of patients had persistent cough compared with 93.4% of patients at the baseline visit. At the final assessment (week 6), 35.3% of patients still reported this symptom. Similarly, although the proportion of people who were free of all symptoms increased considerably over time, only 35.7% of patients were completely free of CAPrelated symptom 6 weeks after the completion of antibiotic therapy.
Predictors of CAP-related symptom resolution. The characteristics of patients with and without CAP-related symptoms 6 weeks after the end of a therapeutic regimen are shown in table 3. In univariate analyses, the following factors were significantly associated with the complete resolution of CAP symptoms: younger age, lower PSI scores, lower systolic blood pressure, lower respiratory rate, higher temperature, higher O 2 saturation, absence of asthma or COPD, treatment in the critical pathway, and use of levofloxacin therapy. In the multivariate model, the absence of COPD (RR, 3.3;
), younger P ! .001 age (RR, 1.2 per 10 years;
), the absence of asthma P p .002 (RR, 2.1;
), and treatment with levofloxacin (RR, 1.7; P p .012 ) were identified as significant predictors (table 4) . P p .010
Prevalence of gastrointestinal symptoms. The proportion of patients who reported any gastrointestinal symptoms was 24.1% at week 2 (figure 2). Abdominal pain, reported by 11.4% of patients, was the most common complaint; 10.1% of patients reported nausea. At week 6, the most common complaint was diarrhea, which was reported by 9.3% of patients. Although the proportion of patients with gastrointestinal symptoms decreased with time, 16 .4% of patients reported at least 1 gastrointestinal symptom at week 6.
Predictors of gastrointestinal symptoms. The characteristics of patients with and without gastrointestinal symptoms at 6 weeks after therapy are shown in table 5. Significant factors that were positively associated with the presence of gastrointestinal symptoms in univariate analyses were presence of asthma, neoplastic or renal disease, and treatment with a macrolide antibiotic. Treatment according to the critical pathway and levofloxacin use were significantly associated with the absence of gastrointestinal symptoms. In the multivariate analysis, 3 significant predictors were identified: the presence of asthma (RR, 2.3;
), renal disease (RR, 5.1; ), and use P p .005 P p .002 of macrolide therapy (RR, 2.2;
, table 6). P p .002
Comments
Our primary finding was that the majority of patients with CAP continued to report у1 symptom of the disease 6 weeks after the discontinuation of antibiotic therapy. This observation is consistent with the 2 reports of Metlay et al. [6, 7] , who showed that in patients who had less severe disease than those evaluated in the current study, 150% of patients reported у1 CAP-related symptom 90 days after treatment [6] . In a group of patients who were less ill (mean PSI score of 120 points lower compared with the patients evaluated in the current study), 35% of patients had symptoms 28 days after treatment [7] . Thus it is not surprising that approximately two-thirds of our patients experienced у1 CAP-related symptom 6 weeks after the completion of antibiotic therapy. Furthermore, the patients we studied were all volunteers who completed sequential questionnaires. It is reasonable to speculate that patients who were unable or unwilling to do so would be even more likely to experience persistent complaints [11] . Therefore our estimate of the prevalence of persistent symptoms likely understates the magnitude of the problem. Clinicians should be aware that persistent symptoms are common, and they should attempt to treat the underlying causes. In addition, further research into the etiology of symptom persistence should be undertaken.
In this regard, the multivariate model identified younger age, Figure 2 . Percentage of cohort patients reporting gastrointestinal symptoms at 2 and 6 weeks after therapy. the absence of asthma or COPD, and levofloxacin therapy as being associated with the complete resolution of symptoms.
Although it is plausible that older patients and those with chronic lung diseases would be more likely to continue to experience pulmonary symptoms after an episode of CAP, an interesting finding is that the initial choice of antibiotic therapy might be important. Patients who received levofloxacin were significantly more likely to be completely free from symptoms at week 6 than those who received other drug regimens (39.8% of patients who received levofloxacin vs. 29.3% of those who received other types of antibiotic therapy; difference, 10.5%, 95% CI, 2.4-18.6). Whether the choice of initial antibiotic therapy might favorably modify the subsequent course of the disease is unknown. Although analysis of these data suggests that levofloxacin may be superior to conventional treatments for CAP, it should be emphasized that our analyses were retrospective and observational. Definitive conclusions regarding the relative efficacy of different antibiotic therapies will require performance of randomized controlled trials. A secondary goal of this study was to evaluate predictors of the occurrence of gastrointestinal symptoms in these patients. Although the prevalence of gastrointestinal complaints decreased with time, 16.4% of people still reported у1 symptom at the final assessment. Predictors for the occurrence of gastrointestinal symptoms included the presence of renal disease or asthma. Because patients with renal disease have a higher incidence of gastrointestinal symptoms from their underlying disease [12] and therapy, it is not surprising that this association was found. Similarly, asthmatics receive treatment with medications that may cause gastrointestinal side effects (glucocorticoids, b-agonists, and theophylline) and are more likely to have gastroesophageal reflux disease [13] . Macrolide use was also a significant predictor. Although the majority of patients in our study were treated with second-generation macrolides (clarithromycin and azithromycin) that are better tolerated than erythromycin, these medications also have a relatively high incidence of gastrointestinal side effects [14] [15] [16] .
The primary limitation of our study is the observational methodology that was used. Like all observational studies, our results may have been susceptible to bias; however, the data regarding persistence of symptoms were collected prospectively with a defined protocol. Neither the patients nor research personnel who collected the data were aware that we would ultimately be using this information to answer the questions identified in the current study.
The second limitation concerns the generalizability of our results. The patients who completed questionnaires were younger and had less severe disease than the entire population of patients with CAP. As noted previously, the extrapolation of these results [17] to sicker patients should be done with caution. Moreover, for these patients, the complete resolution of symptoms may be less of a concern than the occurrence of complications of CAP or other undesirable outcomes. Further studies, which evaluate the resolution of symptoms in patients with more severe CAP, should address this issue.
In conclusion, CAP-related symptoms persisted in the majority of patients 16 weeks after completion of antibiotic therapy. This finding may have important implications for the management of patients with CAP. Furthermore, absence of COPD Table 6 .
Predictors of gastrointestinal symptoms 6 weeks posttherapy. and asthma, younger age, and initial treatment with levofloxacin were identified to be predictors of response. Randomized controlled trials should be performed to evaluate the relative efficacy of different antibiotic therapies on the rate of resolution of symptoms.
